Chen Ye, Zhiliang Lin, Jiaqu Cui, Xiaoqiong Lv, Shaoyi Zhang, Chunlian Ma, Yinmei Yan, Bo Yang, Di Zhao, Hongliang Tian, Ning Li, Qiyi Chen, Huanlong Qin
Department of Colorectal Disease Specialty, Clinical Research Center for Digestive Diseases, The Tenth People's Hospital, Tongji University, Shanghai, China.
Front Med (Lausanne). 2022 May 18;9:830004. doi: 10.3389/fmed.2022.830004. eCollection 2022.
Fecal microbiota transplantation (FMT) is a therapy that involves the transplantation of healthy human fecal microorganisms into the gut of patients to rebuild or consolidate the intestinal microecology. It has been utilized in many diseases. However, FMT had a limited effect on patients with small intestinal diseases because of the unique ecological characteristics of the microorganisms. Thus, we proposed a new microecology transplantation therapy called human intestinal fluid transplantation (HIFT). Human intestinal fluid can be collected through a nasojejunal tube and be made into capsules using the freeze-dried powder method. In addition, strict standards for donor screening and management have been established. We are currently developing a high-standard HIFT preparation system and conducting high-quality clinical studies to validate the safety and efficacy of HIFT combined with FMT.
粪便微生物群移植(FMT)是一种将健康人类粪便微生物移植到患者肠道以重建或巩固肠道微生态的治疗方法。它已被应用于多种疾病。然而,由于微生物独特的生态特征,FMT对小肠疾病患者的效果有限。因此,我们提出了一种新的微生态移植疗法,称为人肠液移植(HIFT)。人肠液可通过鼻空肠管收集,并采用冷冻干燥粉末法制成胶囊。此外,还建立了严格的供体筛选和管理标准。我们目前正在开发一个高标准的HIFT制剂系统,并开展高质量的临床研究,以验证HIFT联合FMT的安全性和有效性。